Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.
This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right decisions about which compounds to take forward to avoid cardiovascular toxicity, the leading cause of safety-related project failure in drug development today.
Read more here: New Drug Discovery Alliance to Tackle High Rate of Failure in Drug Development